Logo

AstraZeneca's Forxiga (dapagliflozin) Receive NMPA's Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study

Share this

AstraZeneca's Forxiga (dapagliflozin) Receive NMPA's Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study

Shots:

  • The updated label includes P-III DECLARE-TIMI 58 study that assesses the effect of Forxiga vs PBO on CV outcomes in 17000+ patients with T2D at risk of CV events also assessed key renal 2EPs- across 882 sites in 33 countries
  • The study demonstrated that Forxiga achieved a significant reduction in the composite EP of hHF or CV death. The trial confirmed the well-established safety profile of Forxiga
  • The NMPA’s label update follows the update to the EU MAA in Aug’2019 and the US FDA’s approval granted in Oct’2019

 ­ Ref: AstraZeneca | Image: Al Jazeera

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions